The Effect of Thymoquinone on Apoptosis of SK-OV-3 Ovarian Cancer Cell by Regulation of Bcl-2 and Bax
- 1 October 2017
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 27 (8), 1596-1601
- https://doi.org/10.1097/igc.0000000000001064
Abstract
We aim to determine how cisplatin, thymoquinone (TQ), and combination regimen can affect apoptosis of cultured SK-OV-3 cells. We also want to explore the mechanism of these influences on the cells' apoptosis by Bcl-2 and Bax gene. Cell Counting Kit-8 assay was used to measure the viability of cultured ovarian cancer cells. Propidium iodide with flow cytometry was used in cell cycle analysis. Thereafter, we used fluorescein isothiocyanate–stained annexin V and propidium iodide to detect the effect of cisplatin, TQ, and combination regimen on apoptosis. Real-time PCR was used to measure the Bcl-2 and Bax levels. Western blotting was used to measure on protein expression levels of Bcl-2 and Bax. In Cell Counting Kit-8 assay, we found that inhibitory effect of TQ was even better than cisplatin, and combination regimen had best inhibitory effect on cell proliferation. In cell cycle analysis, we found all regimens had obvious effect to stop cell cycle in S phase. In apoptosis assay, we found that combination regimen was better to activate cell apoptosis than cisplatin alone. Combination regimen could decrease expression of Bcl-2 and increase expression of Bax more than cisplatin or TQ alone. Thymoquinone and cisplatin had comparable antitumoric effects on SK-OV-3 cells, and combination regimen was even better. Thymoquinone could also activate apoptosis by regulating Bcl-2 and Bax genes. These indicated potential advantage of TQ for ovarian cancer in clinical practice and suggested future clinical trials to confirm its effectiveness.Keywords
This publication has 19 references indexed in Scilit:
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2012
- Recent progress in the diagnosis and treatment of ovarian cancerCA: A Cancer Journal for Clinicians, 2011
- Review on Molecular and Therapeutic Potential of Thymoquinone in CancerNutrition and Cancer, 2010
- RETRACTED: Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potentialBiochemical Pharmacology, 2010
- Activation of NF-κB Signaling by Inhibitor of NF-κB Kinase β Increases Aggressiveness of Ovarian CancerCancer Research, 2010
- Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic CancerCancer Research, 2009
- Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancerGynecologic Oncology, 2009
- Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion–solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oilColloids and Surfaces B: Biointerfaces, 2006
- Worldwide burden of gynaecological cancer: The size of the problemBest Practice & Research Clinical Obstetrics & Gynaecology, 2005